Sutro Biopharma Inc (STRO)

$3.89

-0.1

(-2.51%)

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $3.85
    $4.10
    $3.89
    downward going graph

    1.03%

    Downside

    Day's Volatility :6.1%

    Upside

    5.12%

    downward going graph
  • $2.01
    $6.13
    $3.89
    downward going graph

    48.33%

    Downside

    52 Weeks Volatility :67.21%

    Upside

    36.54%

    downward going graph

Returns

PeriodSutro Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
7.26%
5.3%
0.0%
6 Months
-17.05%
6.3%
0.0%
1 Year
-10.34%
9.2%
0.0%
3 Years
-76.61%
13.1%
-19.9%

Highlights

Market Capitalization
308.0M
Book Value
$1.57
Earnings Per Share (EPS)
-1.88
Wall Street Target Price
12.3
Profit Margin
-74.61%
Operating Margin TTM
-435.05%
Return On Assets TTM
-17.01%
Return On Equity TTM
-81.12%
Revenue TTM
154.1M
Revenue Per Share TTM
2.53
Quarterly Revenue Growth YOY
2.6%
Gross Profit TTM
-42.5M
EBITDA
-96.7M
Diluted Eps TTM
-1.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.46
EPS Estimate Next Year
-3.57
EPS Estimate Current Quarter
-0.92
EPS Estimate Next Quarter
-0.76

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Sutro Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
13
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 216.2%

Current $3.89
Target $12.30

Company Financials

FY18Y/Y Change
Revenue
38.4M
↓ 25.75%
Net Income
-35.3M
↑ 79.38%
Net Profit Margin
-91.93%
↓ 53.88%
FY19Y/Y Change
Revenue
42.7M
↑ 11.24%
Net Income
-55.7M
↑ 57.84%
Net Profit Margin
-130.44%
↓ 38.51%
FY20Y/Y Change
Revenue
42.7M
↓ 0.03%
Net Income
-36.2M
↓ 35.05%
Net Profit Margin
-84.75%
↑ 45.69%
FY21Y/Y Change
Revenue
61.9M
↑ 44.84%
Net Income
-108.7M
↑ 200.17%
Net Profit Margin
-175.62%
↓ 90.87%
FY22Y/Y Change
Revenue
67.8M
↑ 9.52%
Net Income
-119.2M
↑ 9.69%
Net Profit Margin
-175.89%
↓ 0.27%
FY23Y/Y Change
Revenue
153.7M
↑ 126.84%
Net Income
-106.8M
↓ 10.41%
Net Profit Margin
-69.47%
↑ 106.42%
Q4 FY22Q/Q Change
Revenue
8.6M
↓ 65.67%
Net Income
-37.1M
↑ 108.79%
Net Profit Margin
-429.73%
↓ 359.08%
Q1 FY23Q/Q Change
Revenue
12.7M
↑ 46.83%
Net Income
-50.1M
↑ 34.93%
Net Profit Margin
-394.9%
↑ 34.83%
Q2 FY23Q/Q Change
Revenue
10.4M
↓ 17.85%
Net Income
-38.5M
↓ 23.03%
Net Profit Margin
-370.0%
↑ 24.9%
Q3 FY23Q/Q Change
Revenue
16.9M
↑ 62.54%
Net Income
-49.3M
↑ 27.93%
Net Profit Margin
-291.21%
↑ 78.79%
Q4 FY23Q/Q Change
Revenue
113.7M
↑ 571.95%
Net Income
31.1M
↓ 163.03%
Net Profit Margin
27.32%
↑ 318.53%
Q1 FY24Q/Q Change
Revenue
13.0M
↓ 88.56%
Net Income
-58.2M
↓ 287.39%
Net Profit Margin
-447.52%
↓ 474.84%
FY18Y/Y Change
Total Assets
223.1M
↑ 447.33%
Total Liabilities
91.6M
↓ 38.84%
FY19Y/Y Change
Total Assets
156.4M
↓ 29.92%
Total Liabilities
58.6M
↓ 36.05%
FY20Y/Y Change
Total Assets
394.1M
↑ 152.04%
Total Liabilities
62.1M
↑ 5.94%
FY21Y/Y Change
Total Assets
341.4M
↓ 13.37%
Total Liabilities
88.8M
↑ 43.15%
FY22Y/Y Change
Total Assets
406.9M
↑ 19.2%
Total Liabilities
189.9M
↑ 113.74%
FY23Y/Y Change
Total Assets
470.7M
↑ 15.68%
Total Liabilities
321.1M
↑ 69.09%
Q4 FY22Q/Q Change
Total Assets
406.9M
↑ 1.56%
Total Liabilities
189.9M
↑ 11.07%
Q1 FY23Q/Q Change
Total Assets
358.0M
↓ 12.02%
Total Liabilities
172.6M
↓ 9.11%
Q2 FY23Q/Q Change
Total Assets
464.9M
↑ 29.85%
Total Liabilities
310.2M
↑ 79.71%
Q3 FY23Q/Q Change
Total Assets
431.7M
↓ 7.13%
Total Liabilities
319.4M
↑ 2.97%
Q4 FY23Q/Q Change
Total Assets
470.7M
↑ 9.03%
Total Liabilities
321.1M
↑ 0.53%
Q1 FY24Q/Q Change
Total Assets
403.4M
↓ 14.3%
Total Liabilities
305.4M
↓ 4.89%
FY18Y/Y Change
Operating Cash Flow
12.7M
↓ 134.21%
Investing Cash Flow
-80.2M
↓ 345.97%
Financing Cash Flow
170.8M
↑ 1066.64%
FY19Y/Y Change
Operating Cash Flow
-65.0M
↓ 612.68%
Investing Cash Flow
-51.1M
↓ 36.24%
Financing Cash Flow
-4.2M
↓ 102.45%
FY20Y/Y Change
Operating Cash Flow
-67.8M
↑ 4.27%
Investing Cash Flow
604.0K
↓ 101.18%
Financing Cash Flow
269.2M
↓ 6535.16%
FY21Y/Y Change
Operating Cash Flow
-81.7M
↑ 20.47%
Investing Cash Flow
-97.3M
↓ 16211.75%
Financing Cash Flow
3.3M
↓ 98.79%
FY22Y/Y Change
Operating Cash Flow
3.5M
↓ 104.35%
Investing Cash Flow
-35.0M
↓ 64.01%
Financing Cash Flow
48.3M
↑ 1383.81%
Q4 FY22Q/Q Change
Operating Cash Flow
-23.9M
↓ 136.24%
Investing Cash Flow
-37.9M
↓ 51.46%
Financing Cash Flow
12.2M
↓ 59.05%
Q1 FY23Q/Q Change
Operating Cash Flow
-61.0M
↑ 155.58%
Investing Cash Flow
67.5M
↓ 278.06%
Financing Cash Flow
8.8M
↓ 28.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-31.2M
↓ 48.85%
Investing Cash Flow
66.2M
↓ 1.92%
Financing Cash Flow
137.7M
↑ 1471.83%

Technicals Summary

Sell

Neutral

Buy

Sutro Biopharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sutro Biopharma Inc
Sutro Biopharma Inc
29.97%
-17.05%
-10.34%
-76.61%
-63.83%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sutro Biopharma Inc
Sutro Biopharma Inc
NA
NA
NA
-3.46
-0.81
-0.17
NA
1.57
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sutro Biopharma Inc
Sutro Biopharma Inc
Buy
$308.0M
-63.83%
NA
-74.61%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Sutro Biopharma Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 113.72M → 13.00M (in $), with an average decrease of 88.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 31.06M → -58.21M (in $), with an average decrease of 287.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 77.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.5% return, outperforming this stock by 270.1%

Institutional Holdings

  • Suvretta Capital Management, LLC

    7.06%
  • BlackRock Inc

    6.97%
  • Millennium Management LLC

    5.79%
  • MPM Oncology Impact Management LP

    5.01%
  • Vanguard Group Inc

    3.70%
  • Kynam Capital Management, LP

    2.45%

Company Information

at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll

Organization
Sutro Biopharma Inc
Employees
300
CEO
Mr. William J. Newell J.D.
Industry
Health Technology

FAQs